Karyopharm Therapeutics Announces Preclinical Data for Selinexor (KPT-330) in Acute Myeloblastic Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) Models at FASEB Science Research Conferences

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NATICK, Mass., Aug. 7, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company focused on developing first-in-class nuclear transport modulators for the treatment of cancer and other major diseases, announced that a poster titled "Novel inhibitors of CRM1/XPO1 nuclear exporter exhibit [striking] anti-leukemic activity against AML and T-ALL cells while sparing normal hematopoietic cells" was presented today at the Federation of American Societies for Experimental Biology (FASEB) conference on Hematological Malignancies being held in Saxtons River, Vermont, this week as part of the FASEB 2013 Summer Research Conferences series. The poster provided preclinical data showing evidence that Karyopharm's proprietary SINE Exportin 1 (XPO1 or CRM1) antagonists induce apoptosis of leukemic cells in models of AML and ALL.

Help employers find you! Check out all the jobs and post your resume.

Back to news